entertainment -WSS

entertainment

author：focus 2025-10-02 22:56:24 - browse：23729

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Carbon Health diabetes program, a test of data

Wikipedia

WSS

American taxpayers paid $1.8 trillion in health care costs in 2022

JPM pitch from hospitals? Revenue streams outside of patient care

Allen Institute goes after foundational questions, CEO Costa says

Healthy food access boosts outcomes in two studies

Physician assistants need a new name. Here's what it should be

Study suggests new cause of Down syndrome: cells linked to aging

focus

entertainment

leisure time

Medicare details structure of new drug price negotiation program

Healthy food access boosts outcomes in two studies

Medical leaders decry Supreme Court decision on affirmative action

Medical school prerequisites are outdated

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Physician assistants need a new name. Here's what it should be

Medical records are filled with copy

Type 2 diabetes prevention programs work at large scale: study

United colonoscopy coverage change 'may cost lives,' doctors say

What is STAT's opinion section for?

focus

How state and local governments are sidelining science

Cancer diagnosis changes perspective doctor, former hospital CEO

Today's health inequities arise from racist U.S. history, say experts

NIH chief: government has fallen behind pharma on clinical trials

Stories you might have missed in 2023: health, science, medicine

Study suggests Covid rebound is far more common with Paxlovid than without

Wikipedia

hotspot

hotspot

entertainment